Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR_IIV) in health childrenWATSON, B. M; LAUFER, D. S; KUTER, B. J et al.The Journal of infectious diseases. 1996, Vol 173, Num 3, pp 731-734, issn 0022-1899Article

Varicella vaccine (VARIVAX) in healthy children and adolescents : results from clinical trials, 1987 to 1989JO WHITE, C; KUTER, B. J; HILDEBRAND, C. S et al.Pediatrics (Evanston). 1991, Vol 87, Num 5, pp 604-610, issn 0031-4005Article

Isolated antibody to hepatitis B surface antigen and response to hepatitis B vaccinationWERNER, B. G; DIENSTAG, J. L; KUTER, B. J et al.Annals of internal medicine. 1985, Vol 103, Num 2, pp 201-205, issn 0003-4819Article

Live Oka/Merck varicella vaccine in healthy children: further clinical and laboratory assessmentWEIBEL, R. E; KUTER, B. J; NEFF, B. J et al.JAMA, the journal of the American Medical Association. 1985, Vol 254, Num 17, pp 2435-2439, issn 0098-7484Article

Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R®_II, VARIVAX® and TETRAMUNE® in healthy children vs. concomitant injections of M-M-R®_II and TETRAMUNE® followed six weeks later by VARIVAX®SHINEFIELD, H. R; BLACK, S. B; STAEHLE, B. O et al.The Pediatric infectious disease journal. 1998, Vol 17, Num 11, pp 980-985, issn 0891-3668Conference Paper

Duration of protection from clinical hepatitis A disease after vaccination with VAQTA®WIENS, B. L; BOHIDAR, N. R; PIGEON, J. G et al.Journal of medical virology. 1996, Vol 49, Num 3, pp 235-241, issn 0146-6615Article

Oka/Merck varicella vaccine in healthy children : final report fo a 2-year efficacy study and 7-year follow-up studiesKUTER, B. J; WEIBEL, R. E; GUESS, H. A et al.Vaccine. 1991, Vol 9, Num 9, pp 643-647, issn 0264-410XArticle

Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB® vaccines in healthy children twelve to eighteen months oldREUMAN, P. D; SAWYER, M. H; KUTER, B. J et al.The Pediatric infectious disease journal. 1997, Vol 16, Num 7, pp 662-667, issn 0891-3668Article

Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax®) in healthy adolescents and adultsKUTER, B. J; NGAI, A; PATTERSON, C. M et al.Vaccine. 1995, Vol 13, Num 11, pp 967-972, issn 0264-410XArticle

Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations : an overviewNALIN, D. R; KUTER, B. J; WIENS, B et al.Journal of hepatology. 1993, Vol 18, pp S51-S55, issn 0168-8278, SUP2Conference Paper

Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP-IPV-PRP∼T-HBs) combination vaccineSTOJANOV, S; LIESE, J. G; WATSON, M et al.Vaccine. 2007, Vol 25, Num 43, pp 7549-7558, issn 0264-410X, 10 p.Article

Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy childrenNGAI, A. L; STAEHLE, B. O; KUTER, B. J et al.The Pediatric infectious disease journal. 1996, Vol 15, Num 1, pp 49-54, issn 0891-3668Article

Modified cases of chickenpox after varicella vaccination : correlation of protection with antibody responseJO WHITE, C; KUTER, B. J; ELLIS, R. W et al.The Pediatric infectious disease journal. 1992, Vol 11, Num 1, pp 19-23, issn 0891-3668Article

Association of steroid therapy with vaccine-associated rashes in children with acute lymphocytic leukaemia who received Oka/Merck varicella vaccineLYDICK, E; KUTER, B. J; ZAJAC, B. A et al.Vaccine. 1989, Vol 7, Num 6, pp 549-553, issn 0264-410XArticle

Live attenuated varicella virus vaccine: efficacy trial in healthy childrenWEIBEL, R. E; NEFF, B. J; SCOLNICK, E. M et al.The New England journal of medicine. 1984, Vol 310, Num 22, pp 1410-1415, issn 0028-4793Article